OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia	410
Impact of Multiple Prescriptions With Anticholinergic Properties on Adverse Clinical Outcomes in the Elderly: A Longitudinal Cohort Study in Taiwan	255
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study	229
Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID‐19: A Nationwide Cohort Study in South Korea	186
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients	160
Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease	158
Collaborative Real‐World Evidence Among Regulators: Lessons and Perspectives	136
On the Concepts, Methods, and Use of “Probability of Success” for Drug Development Decision‐Making: A Scoping Review	109
Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency	95
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	91
Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers	80
Optimal Trough Concentration of Tacrolimus in Pediatric Patients With Primary Nephrotic Syndrome	75
	74
Cerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration	74
Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women	67
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported	60
The Impact of the CYP2D6 “Enhancer” Single Nucleotide Polymorphism on CYP2D6 Activity	59
Artificial Neural Network vs. Pharmacometric Model for Population Prediction of Plasma Concentration in Real‐World Data: A Case Study on Valproic Acid	56
Patient‐Centric Clinical Pharmacology: A Journey from Discovery to Recovery	55
	53
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study	51
The European List of Key Medicines for Medical Education: A Modified Delphi Study	50
Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project	50
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV	49
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance	49

Population‐Based Signals of Antidepressant Drug Interactions Associated With Unintentional Traumatic Injury	48
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	46
Trends in Clinical Pharmacology and Therapeutics	44
Considerations for Human ADME Strategy and Design Paradigm Shift(s) – An Industry White Paper	42
Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration	41
Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men	41
Neurodegenerative Diseases: The Value of Early Predictive End Points	40
Advancing Innovations in Biosimilars	39
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	38
On the Manufacturers of Biosimilars in Asia	38
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations	37
A Multipurpose First‐in‐Human Study With the Novel CXCR7 Antagonist ACT‐1004‐1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker	37